linjc16/ctgov huggingface dataset:
Patient Acceptance of Whole Body Magnetic Resonance Angiography

Study Overview
=================
Brief Summary
-----------------
Investigation of how the patients experience whole body MRA. After the WB-MRA the patients will fill in a questionnaire, that contains questions about the WB-MRA procedure and how the patient felt during the examination. We expect that the patients will report a high degree of satisfaction with the WB-MRA procedure, with little discomfort.

Detailed Description
-----------------
WB-MRA is performed in patients referred for conventional x-ray based angiography. The WB-MRA is performed first in all patients. After both examinations are completed the patients will be asked to fill in a questionnaire containing questions about their experience of the 2 procedures. We will then compare the results for the procedures.

Official Title
-----------------
Whole Body Magnetic Resonance Angiography: Questionnaire Examination of Patient Acceptance.

Conditions
-----------------
Atherosclerosis, Intermittent Claudication, MRI

Intervention / Treatment
-----------------
* Procedure: Whole body magnetic resonance angiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic lower extremity ischemia (claudication, ischemic wounds) Referred to digital subtraction angiography (DSA) Exclusion Criteria: Renal insufficiency (GFR < 30 ml/min) Contra-indications for MRI-examination (claustrophobia, metal-implants, pacemaker) Dementia Pregnancy/lactation Allergy to gadolinium based MRI contrast agents Acute disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Whole body magnetic resonance angiography|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient acceptance of Whole body MRA |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Magnetic resonance, whole body, angiography, questionnaire
Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells

Study Overview
=================
Brief Summary
-----------------
Intrauterine injection of hCG around the time of implantation may increase endometrial Treg cells and improve implantation. It has been demonstrated that regulatory T cells expand during pregnancy. hCG was found to be secreted by the embryo immediately after fertilization and has chemoattractant properties to Treg cells.

Detailed Description
-----------------
Aim of the work: To study the effect of intrauterine injection of human chorionic gonadotrophin on the endometrial T regulatory cells (Treg cells)and the electromicroscopic endometrial characteristics. Background: It has been demonstrated that regulatory T cells expand during pregnancy and are present at the feto-maternal interface at very early stages in pregnancy. Rational: Intrauterine injection of hCG around the time of implantation may increase endometrial Treg cells and improve implantation. Methods: Intrauterine injection of 100 IU hCG will be done followed by endometrial biopsy to check for Treg cells and pinopodes.

Official Title
-----------------
The Effect of Intrauterine Injection of Human Chorionic Gonadotrophins (hCG) on the Endometrial T-regulatory Cells and the Electronmicroscopic Endometrial Characteristics

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: human chorionic gonadotrophin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male factor infertility Ovulatory factor infertility Unexplained infertility Female age less than 39 Exclusion Criteria: Azoospermia Tubal factor infertility Pelvic endometriosis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intrauterine hCG<br>intrauterine injection of 100 hCG followed by endometrial biopsy | Drug: human chorionic gonadotrophin<br>* intrauterine injection of 100 IU hCG followed by endometrial biopsy .<br>* Other names: choriomon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the presence of Treg cells and pinopodes in the endometrium |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hCG, Treg cells, implantation, pinopodes, endometrium
Efficacy and Safety of Neosil on Chronic Effluvium

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of Neosil in the treatment of chronic effluvium

Official Title
-----------------
Randomized Clinical Trial, Placebo Controlled and Active Comparator, to Evaluate Efficacy and Safety of Neosil in Chronic Effluvium

Conditions
-----------------
Chronic Telogen Effluvium

Intervention / Treatment
-----------------
* Drug: Neosil complete
* Drug: Pantogar
* Drug: Neosil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who present hair loss for more than 6 months; Do not use other possible cosmetic or dermatological treatments, during the trial; Not change the diet during the trial and not be any restrictive diet during this period. Exclusion Criteria: Pregnancy or risk of pregnancy and lactating patients; Use of any products to promote hair growth within the 6 months prior to the Baseline Visit; History of hair transplants; Current skin disease; History hypersensitivity to the active ingredients used in the study; Participation in clinical trial in the year prior to this study; Known history of non controled systemic disease (diabetes, hypertension, anemia, iron deficiency, and others); Gastric diseases; Smoker; History of systemic disease (HIV, non specify autoimmune disease, hepatitis, and others).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neosil complete<br>The patient will take the tablets, as follow: 3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and 2 tablets of Neosil Oral, per day - during the last 12 weeks. | Drug: Neosil complete<br>* Oral, during 24 weeks.<br>|
| Experimental: Pantogar<br>The patient wil take the tablets, as follow: 3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and 3 tablets of Pantogar, Oral, per day - during the last 12 weeks. | Drug: Pantogar<br>* Oral, placebo for 12 weeks and pantogar for 12 weeks.<br>|
| Experimental: Neosil<br>The patient will take the tablets, as follow: 2 tablets of Neosil Oral, per day - during the 12 weeks. | Drug: Neosil<br>* Oral, during only 12 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hair density |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and severity of adverse events recorded during the study |  | 24 weeks |
FOAM-study, Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins

Study Overview
=================
Brief Summary
-----------------
Varicose vein disease is a common health problem, which causes much discomfort to patients. Nowadays treatment modalities for greater saphenous veins include surgery and duplex guided foam sclerotherapy. These are two equally accepted and applied treatments for the same patient population. Choice of treatment often depends on the referral preference of the General Practitioner. Until now data are missing which treatment is more cost effective. The current proposal aims at comparing the effects, costs and patient preferences between duplex guided foam sclerotherapy and surgery in the treatment of greater varicose veins.

Official Title
-----------------
FOAM-study Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins: a Randomized Controlled Study

Conditions
-----------------
Varicose Vein Disease

Intervention / Treatment
-----------------
* Procedure: high ligation and stripping (surgery)
* Procedure: FOAM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: incompetence of great saphenous vein for minimal 20 cm life expectancy at least 3 years open and competent deep venous system willing to undergo both treatments Exclusion Criteria: active ulcer signs of deep venous thrombosis with duplex incompetence of the deep venous system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: high ligation and stripping<br>surgery consisting of high ligation in combination with long saphenous stripping | Procedure: high ligation and stripping (surgery)<br>* surgery consisting of high ligation in combination with long saphenous stripping<br>|
| Active Comparator: duplex guided foam sclerotherapy<br>duplex guided foam sclerotherapy | Procedure: FOAM<br>* duplex guided foam sclerotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cumulative probability of recurrent varicose vein within 24 months after treatment |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life (as measured by EuroQol-5D) |  | 24 months | 
| patient preferences (as measured by conjoint analysis) |  | 24 months | 
| direct Health care costs | materials, operation costs, personnel costs | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Incompetence of the great saphenous vein.
Evaluation of the Main Determinants of Patient Acceptability of the Bowel Cleansing Procedure, and of Success of Bowel Cleansing and Caecal Intubation

Study Overview
=================
Brief Summary
-----------------
Several factors are important in achieving a successful colonoscopy, including patient acceptability of the bowel cleansing procedure and the overall quality of cleansing. This observational study has been designed to explore the main determinants of acceptability of the bowel cleansing procedure to the patient in an Italian real life setting. In addition, the study is to examine the determinants of quality of bowel cleansing and describe aspects of the technical performance of the colonoscopy (time to reach the caecum and adenoma detection rate).

Official Title
-----------------
Multicentre, Observational, Prospective Study, Conducted on Italian Out-patients Undergoing Colonoscopy, for the Evaluation of the Main Determinants of the Patient's Acceptability of Bowel Cleansing Procedure, and of the Success of Bowel Cleansing and Caecal Intubation

Conditions
-----------------
Routine Colonoscopy

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent obtained prior to inclusion. Male and female outpatients, aged ≥ 18, treated with bowel cleansing preparation the day before undergoing routine colonoscopy at selected participating centres. Exclusion Criteria: Children and adolescents aged less than 18 years. Pregnant or breastfeeding women. Listed contra-indications to the relevant product used for the bowel cleansing procedure. Patients having been submitted to a previous colonoscopy over the last five years. Patients who have taken laxative enemas the day preceding the colonoscopy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colonoscopy patients<br>Patients undergoing with bowel cleansing procedures according to the clinics' usual routine | Other: No intervention<br>* This was an observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients acceptability of the procedure |  | One day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to reach the caecum |  | One day | 
| Adenoma detection rate |  | One day |
Human Skin Aging: Clinical Parameters and Gene Expression Profiling

Study Overview
=================
Brief Summary
-----------------
Skin aging is a complex process involving genetic and environmental factors. The investigators hope to learn more about how human genes and their function can contribute to skin aging and human health.

Detailed Description
-----------------
This study includes answering a survey on prior sun exposures, donating two small pieces of skin (4mm each), one blood draw, complexion analysis, photographs, and non-invasive tests such as skin surface lipid analysis. Your blood and tissue will be sent for DNA analysis and gene expression profiling.

Official Title
-----------------
Human Skin Aging: Clinical Parameters and Gene Expression Profiling

Conditions
-----------------
Ageing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy female, age 18 or older, Fitzpatrick type 1 or 2 skin, able to read and understand written consent form, body mass index normal or overweight range, willing to take blood tests and donate skin samples Exclusion Criteria: pregnant or lactating, history of cosmetic surgery affecting the face, use of prescription anti-aging medications for 2 weeks prior to study, use of dietary supplements for 2 weeks prior to study, use of tanning beds or excessive light exposure (>2 hours) in the past 2 weeks, medical conditions which at the discretion of the investigator will have significant impact on ability to judge subjects' skin characteristics and age, sunless tanner use in past 2 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy females aged >=18<br>Healthy female volunteers of skin type I or II | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of age related gene expression changes in skin |  | Cross sectional | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ageing
Serum Lactate Trend in Liver Resection

Study Overview
=================
Brief Summary
-----------------
The study aimed to evaluate the correlation between the serum lactate concentration ed cumulative Pringle time after liver resection. In addition, the correlation between lactate clearance and clamping time was investigated.

Detailed Description
-----------------
During liver resection high serum lactate (sLac) concentration can be related to several clinical factors: impairment in lactate metabolism (i.e. extraction and utilization by the liver) or overproduction by splanchnic tissues; restrictive fluid regimen in order to limit the intraoperative back-flow bleeding; ischemia-reperfusion syndrome. However, the Pringle maneuver (temporary clamping of the hepatic hilum) seems having a sensible effect in inducing a significant increase in sLac levels during liver resection, particularly in the event of compromised liver function such as in cirrhosis. Although the peak of sLac concentration may correlate with outcome, the lactate clearance (cLac) seems to be a better predictor. To date, this relationship has been mainly demonstrated in severe sepsis and shock septic. However, the effective correlation between the cumulative clamping time and cLac has not been clearly investigated. The correlation between cumulative hepatic ischemic time and sLac trend in the perioperative period after liver resection with intermittent PM was investigated.

Official Title
-----------------
Serum Lactate Trend in Liver Resection With Intermittent Pringle Maneuver: The Square-Root Shape

Conditions
-----------------
Lactase Persistence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for liver resection for hepatic tumors Exclusion Criteria: Patients who received blood transfusion or affected by chronic renal failure were excluded

Ages Eligible for Study
-----------------
Minimum Age: 34 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum lactate concentration trend after liver resection |  | within the first 30 days after surgery |
Effect of Prednisone onTregs and TH17

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to see whether systemic corticosteroids (such as Prednisone) have an effect on the peripheral blood Treg and Th17 function in patients with CRS. Patients are taking prednisone as part of their routine medical care.

Official Title
-----------------
Effect of Prednisone on Peripheral Blood T-cell Function (Tregs and Th17) in Patients With Chronic Rhinosinusitis (CRS)

Conditions
-----------------
Chronic Rhinosinusitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of CRS. A CT scan performed in the last year depicting the severity of the disease or nasal polyps on endoscopy. Symptomatic at the time of entry into the study as determined by scores ≥ 1.4 on the Rhinosinusitis disability index Exclusion Criteria: Women who are pregnant or breastfeeding. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, diabetes, osteoporosis, cataracts, glaucoma, neurological, oncologic, liver disease or a contraindication to taking prednisone). Use of any other investigational agent in the last 30 days. Use of clinical drugs like antihistamines, leukotriene modifiers, intranasal steroids, systemic corticosteroids in the last 15 days or immunotherapy in the last year. Upper respiratory infection within 14 days of study start Smoking within the last 2 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal control<br> | |
| Patient treatment group<br>Treatment with prednisone | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treg cell numbers |  | pre treatment vs post treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokine levels in cultured PBMCs |  | pre vs post treatment |
Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
Studies in the past have shown that yoga could relieve stress which is the most common trigger for recurrent episodes of atrial fibrillation. Breathing exercises in yoga are found to influence the autonomic nervous system (particularly parasympathetic) and thus reduce palpitations. This study hypothesizes that patients with atrial fibrillation might benefit by practicing yoga. Yoga may also help to better control heart rate and rhythm when used in combination with usual medical management.

Official Title
-----------------
The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Paroxysmal Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: Yoga training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with paroxysmal atrial fibrillation ages 25-80 Exclusion Criteria: Advanced malignancy or severe co-morbid conditions such as severe heart failure and with life expectancy less than 1 year Pregnant women Unmedicated or uncontrolled high blood pressure A past history of pneumothorax Severe cervical spondylitis and cervical, thoracic or lumbar disc prolapse Carotid stenosis History of psychosis or substance abuse History of epilepsy Glaucoma History of total hip replacement Ablation within 3 months of the start date of study Patients who have not seen a cardiovascular physician in the last year

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Yoga training | Other: Yoga training<br>* Yoga training for 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency and duration of atrial fibrillation episodes |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, yoga